HomeCompareSPMXF vs ABBV

SPMXF vs ABBV: Dividend Comparison 2026

SPMXF yields 1333.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPMXF wins by $241528700.51M in total portfolio value
10 years
SPMXF
SPMXF
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full SPMXF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SPMXF vs ABBV

📍 SPMXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPMXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPMXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPMXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPMXF
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SPMXF beats the other by $178,904,481,040,489.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPMXF + ABBV for your $10,000?

SPMXF: 50%ABBV: 50%
100% ABBV50/50100% SPMXF
Portfolio after 10yr
$120764350.36M
Annual income
$105,237,930,048,589.16/yr
Blended yield
87.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SPMXF
No analyst data
Altman Z
4.7
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPMXF buys
0
ABBV buys
0
No recent congressional trades found for SPMXF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPMXFABBV
Forward yield1333.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$241528700.61M$102.3K
Annual income after 10y$210,475,860,072,406.56$24,771.77
Total dividends collected$239239876.27M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPMXF vs ABBV ($10,000, DRIP)

YearSPMXF PortfolioSPMXF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$144,033$133,333.33$11,550$430.00+$132.5KSPMXF
2$1,948,924$1,794,807.89$13,472$627.96+$1.94MSPMXF
3$24,782,219$22,696,870.86$15,906$926.08+$24.77MSPMXF
4$296,245,945$269,728,970.81$19,071$1,382.55+$296.23MSPMXF
5$3,330,378,004$3,013,394,842.54$23,302$2,095.81+$3330.35MSPMXF
6$35,223,684,321$31,660,179,856.69$29,150$3,237.93+$35223.66MSPMXF
7$350,636,384,108$312,947,041,885.16$37,536$5,121.41+$350636.35MSPMXF
8$3,286,630,500,315$2,911,449,569,318.85$50,079$8,338.38+$3286630.45MSPMXF
9$29,021,346,295,663$25,504,651,660,325.88$69,753$14,065.80+$29021346.23MSPMXF
10$241,528,700,608,766$210,475,860,072,406.56$102,337$24,771.77+$241528700.51MSPMXF

SPMXF vs ABBV: Complete Analysis 2026

SPMXFStock

Supermax Corporation Berhad, an investment holding company, manufactures, distributes, and markets medical gloves and contact lenses in Malaysia. The company offers various types of natural rubber and nitrile latex gloves, as well as personal protective equipment. It is also involved in the trading, importing, and distribution of latex gloves; generation of biomass energy; marketing and distribution of healthcare products and medical devices; and property holding activities. The company sells its products to laboratories, pharmacists, hospitals, doctors, and surgeons under the Supermax, Aurelia, and Maxter brands. It also exports its products to approximately 165 countries, including the United States, the European Union, the Middle East, Asia, and the South Pacific countries. The company was founded in 1987 and is headquartered in Sungai Buloh, Malaysia.

Full SPMXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SPMXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPMXF vs SCHDSPMXF vs JEPISPMXF vs OSPMXF vs KOSPMXF vs MAINSPMXF vs JNJSPMXF vs MRKSPMXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.